The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...

Sens. Susan Collins (R-ME) and Claire McCaskill (D-MO) sent five identical letters late last week to opioid overdose antidote manufacturers Pfizer, Amphastar Pharmaceuticals, Mylan, Kaléo Pharma and ...

Pfizer’s dividend yield has surged to 6.3% after a 55% share price drop since 2021, prompting concerns about its sustainability. Management has pledged to maintain the payout, but payout ratios above ...

The healthcare giant has been investing heavily in its future growth.

“What does your husband do?” Undoubtedly the man who asked me thought it was a harmless question. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive content.

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...